SIGs

Special Interest Groups

Statistical Leaders Meeting & EFPSI Council Mtg

18_19 JUN 2013

Links via EFSPI website



SIGs - Stats Leaders Mtgs

Core Topics Stats Mtg	2013	2012	2011	2010	Link to SIG
Risk - Benefit			update	intro+discuss	Benefit-Risk
Assessing Risk Benefit - Roadmap	update	intro+discuss			Benefit-Risk
Model Based Drug Development			intro+discuss		Modeling & Simulation
Totality of Evidence - observational data			intro+discuss		Epidemiology & Safety
Health Technology Assesment (CER)			update	intro+discuss	HTA (CER)
Comparative drug effects - Network meta-analyses			intro+discuss		HTA (CER)
					Biomarkers
Medical Devices	intro+discuss				Medical Devices
					Toxicology
Adaptive statisticians & the challenges beyond Clinical Trials		intro+discuss			Epidemiology & Safety; Career Path
					Professional
EMA Clinical Trial Data Transparency	intro+discuss				Transparency
Professional development		paper	update	intro+discuss	Career Path
accreditation			intro+discuss		Accreditation

SIG: Benefit - Risk

- Initiated February 2012

Membership:

–Ian Hirsch (AstraZeneca-chair of SIG)
–Susan Shepherd (Amgen)
–Martin Gebel (Bayer)
–Rebecca Sudlow and George Quartey (Roche and George link to epidemiology/safety SIG & QSPI)
–Guenter Heimann and Ekkehard Glimm (Novartis)
–Maylis Coste and Veronique Robert (IRIServier)
–Dan Evans (Pfizer)
–Yunxia Lu (Karolinska Institutet)
–Alan Phillips (Icon)
–Alberto Garcia-Hernandez (Astellas)
–Alexander Schacht (Eli Lilly)
–Mario Ouwens (Abbott)
–Shahrul Mt-Isa (Imperial College)
–Del Jones (GSK)

–In addition Andrew Thomson from the MHRA is not officially a member but attends the SIG meetings.

SIG: Benefit - Risk

Achievements 2012 - 2013:

- Finalized charter and scope
- Solicited feedback from:
  - *PSI Board Meeting May 2012*
  - *EFSPI Statistical Leaders Meeting (and subsequent EFSPI Council mtg)*
- Outputs almost final for
  - *Blueprint-including feedback*
  - *Summary of key literature reviews and initiatives*
  - *3 industry case studies (AZ, Roche and GSK) and link to IMI Case studies to share*
- "Introduction to" session at PSI Conference 2013

.

SIG: Benefit - Risk

2013-2014 Plan

- Presentation on Roadmap on Statistical Leaders Meeting

- Joint EFSPI/PSI Benefit-Risk One day meeting: 17 SEP 2013: at RSS, London
  - Includes both industry and IMI case studies

- Share:
  - Literature reviews/initiatives
  - Case studies

- Outputs:
  - Points to consider document – needs to be evolving
  - Publications -topics to be decided on which need a unique slant
  - External colaboration
    - Link to QSPI-potential global reach-chairs meeting
    - Link to COMET initiative for core outcome sets
    - Strong links to IMI WP5 initiative- cross membership

SIG: Benefit - Risk

Support needed from EFSPI:

- **Interactive platform and within company "push"** to share information
  - for PTC, case studies, example code etc
- **More case studies** – anonymised ok but why only GSK, AZ and Roche?
- Greater synergies with **external groups** e.g. QSPI?

SIG: Biomarkers

- Became joint PSI-EFSPI SIG in 2011

Membership (SIG committee):

• Martin Jenkins	AstraZeneca; Chair of SIG
• Nigel Dallow	GSK
• Chris Harbron	AstraZeneca
• Athula Herath	MedImmune
• Jayantha Ratnayake	Roche
• Tony Sabin	Amgen
• Trevor Smart	Lilly
• Charlotte Vignal	Roche
• David Wille	GSK

SIG: Biomarkers

Achievements (2012-2013):

- Face-to-face meeting on “the statistical validation of biomarkers” (~40 attendees)
- PSI Journal club presentation
- Collation of materials for training course
- Review of regulatory guidance on biomarkers in histology studies

Plan 2013:

- Practical training course for statisticians in biomarker use and analysis in conjunction with PSI: To be held 25th & 26th September in Ascot, UK. Registration now open on PSI website.
- Developing a webpage of resources
- Planning a further face-to-face scientific meeting

SIG: Biomarkers

Papers / Best Practices / Handbooks published:

- Manuscript in Pharmaceutical Statistics 2011, 10:
  - *"A statistician's perspective on biomarkers in drug development"*

Support needed from EFSPI, or any other request:

- Sufficient support has largely come from PSI to date, although EFSPI link formalises the fact that many statisticians from across Europe attend our events
- Advertisement of training course and other future events via EFPSI would be appreciated

SIG: Toxicology

- Exists already 6 years

Membership:

- Gareth Thomas Huntingdon Life Sciences, Chair of SIG
- Jim Saul Covance
- Mike Aylott GSK
- Sarah Kirk AstraZeneca
- Helena Geys Johnson & Johnson

SIG: Toxicology

Achievements 2012 - 2013:

- Organized 2 day workshop in Oct 2011
- Organized 2 day workshop in Mar 2013

  The agenda covered the following topics:

  - Combining safety pharmacology endpoints into toxicology studies
  - Microsampling
  - Recommendations on the use of historical control data
  - Combining sexes in analyses.
- a list of over 40 affiliates on our e-mail distribution list.

Plan for 2013 and beyond:

- Organize another workshop for Oct 2014
- Considering webinars and publications to progress topics discussed at last workshop

SIG: Toxicology

Papers / Best Practices / Handbooks published:

- Manuscripts in Pharmaceutical Statistics 2011, 10:
  - *“An assessment of the statistical methods used to analyse toxicology studies”*
  - *“Review of the statistical analysis of the dog telemetry study.”*
  - “*Recommendations on the statistical analysis of the Comet assay.*”

Support needed from EFSPI, or any other request:

- If interested in joining the mailing list, email ThomasG@UKOrg.huntingdon.com

SIG: Epidemiology and Drug Safety

Membership:

• George Quartey	Genentech
• Maurille Feudjo-Tepie	Amgen
• Joseph Kim	Quintiles
• Nilani Liyanage	Ipsen
• Jason Wang	Novartis
• Jonathan Alsop	Numerus
• Volker Hosel	StatSciConsult
• David Prieto-Merino	LSHTM
• Alex Thompson	Roche
• Arlene Gallagher	MHRA
• Athula Herath	MedImmune
• Gerry Downy	Amgen
• Charles Warne	Amgen
• Guiyuan Lei	Roche

EFSPI SIG: Epidemiology and Drug Safety

Achievements 2012-2013:

- Organized parallel session for PSI Annual Conference with MHRA

Plan 2013-2014:

- Asia-Pacific DIA conference presentation on Statistical Issues and Best Practices for MA of Drug Safety (15 May 2013, Beijing)
- Poster Presentation at ICPE Conference, Montreal, August 2013
- Point to consider document on Pharmaco-epidemiology and Drug Safety (1st Draft completed)
- Handbook on Pharmaco-epidemiology for statisticians (1st Draft)

SIG: Epidemiology

Papers / Best Practices / Handbooks published:

- Three manuscripts in Pharmaceutical Statistics 2011, 10:
  - *"A review of risk measures in pharmacoepidemiology with tips for statisticians in the pharmaceutical industry"*
  - *"Opportunities for minimization of confounding in observational research"*
  - *"Why a Bayesian approach to safety analysis in pharmacovigilance is important"*

- Support needed from EFSPI, or any other request:
  - None

SIG: Modelling and Simulation

Membership:

• Chris Campbell	Mango Solutions; Chair
• Ad Theeuwes	Astellas
• Benoit Beck	Axiosis
• Carl-Frederik Burman	AstraZeneca
• Martin Scott	Numerus
• Michael O'Kelly	Quintiles
• Michelle Jones	Covance
• Tom Parke	Tessella
• Vincent Haddad	Amgen
• Vladimir Anisimov	Quintiles

SIG: Modelling and Simulation

Achievements (2012-2013):

- SIG provided two speakers to the EFPSI Modelling & Simulation meeting on 13 September 2012.
- SIG delivered a practical course on Modelling & Simulation on 24-25 October.
- It is also developing a Best Practice document for Modelling and Simulation.

Plan 2013:

- Organizing with EFSPI meeting on Modelling and Simulation
- Discussions for applicability of Bayesian Methods in M&S

SIG: Modeling and Simulation

Papers / Best Practices / Handbooks published:

- Manuscript in Pharmaceutical Statistics 2011, 10:
  - *“Modelling and simulation in the pharmaceutical industry—some reflections”,* CF Burman, SJ Wiklund
  - *“Predictive event modelling in multicenter clinical trials with waiting time to response”,* VV Anisimov

Support needed from EFSPI, or any other request:

- …

SIG: Medical Devices

Medical Device can be defined as any healthcare product that does not achieve its principal intended purposes by chemical action or by being metabolized.

SIG: Medical Devices

- Formed in 2010.
- Aims of the SIG are:
  - Create visibility on biostatistics activities for medical devices,
  - Strengthen methodological aspects in the development of medical devices,
  - Create an expert group identified by authorities,
  - Share Good Statistical Practice.
- Medical Device group works by teleconferences.

SIG: Medical Devices

Membership:

Group Leader: Roland MARION-GALLOIS

	Affiliation	Country
Abdallah ABOUIHIA	Medtronic	Switzerland
Mikael ASTROM	StatCons	Sweden
François AUBIN	Cardinal Systems	France
Hubert BEAUMONT	Median Technologies	
Gilles BERDEAUX	IMS Health	Belgium
Pascal CANDOLFI	Edwards	Switzerland
Javier CASTANEDA	Medtronic	Netherland
Tiziana De SANTO	Medtronic	Italy
Julie DOREY	Creativ'Ceutical	France
Marie-Christine FALCOU	Institut Curie	France
Claudio GARUTTI	Medtronic	Netherland
Bart GERRITSE	Medtronic	Netherland
Sophie GROSZ	Biomerieux	France
Florent GUELFUCCI	Creativ'Ceutical	France
Pierre-Philippe LUYET	Clinopsis	Switzerland
Khaled MAMAN	Creativ'Ceutical	France
Roland MARION-GALLOIS	Medtronic	Switzerland
Nicolas MOLINARI		France
Jonas RANSTAM	NMC, Lund University	Sweden
Gérard TAP		France
Rod TAYLOR		UK
Françoise TONDU		France
Mondher TOUMI	Creativ'Ceutical	France
Peter TREASURE	Free-lance	UK
Anne-Lise VATAIRE	Creativ'Ceutical	France
Martin WADEPUHL	Free lance	Germany

SIG: Medical Devices

- Activity in 2011:
  - Review the environment context
  - Place of post-approval registries
  - Is there a place for statistical methodology in the recast of the Medical Device EU Directive?
- Activity in 2012:
  - Adjustment on baseline
  - Creation of a LinkedIn group
- Plan for 2013:
  - Categorize Medical Devices according to clinical research needs
  - Technological watch on methodological aspects for Medical Devices (guidelines, regulation…)
  - Future European regulation for Medical Device

SIG: Medical Devices

Papers / Best Practices / Handbooks published:

- None

Support needed from EFSPI, or any other request:

- Letter to EU deputies concerning the lack of methodological reference in the proposed text for a new regulation (September 2013 ?)
- Maintain and develop inclusion of MD

SIG: HTA

- formed in 2010

Membership:

• Chrissie Fletcher	Amgen; Chair of SIG
• Tim Auton	Astellas
• Marie-Laure Bravo	Celgene
• Christy Chuang-Stein	Pfizer
• John Davies	GSK
• Christoph Dierig	Bayer
• Pierre Ducournau	Roche
• Pietri Guilhem	Heron
• Christoph Gerlinger	Bayer
• Byron Jones	Pfizer/Novartis
• Kim Mark-Krudsen	Leo
• Jan McKendricks	Consultant
• Patrick Moneuse	Vifor Pharma
• Marie-Ange Paget	Eli Lilly
• Tim Reason	Abacus
• Carol Reid	Roche
• Martin Scott	Numerous Ltd
• Fred Sorenson	Xcenda
• Helen Tate	Consultant
• Claire Watkins	AstraZeneca
• Caroline Whately-Smith	Consultant

SIG: HTA

Achievements 2012-2013:

- Round table discussion with Prof Mark Sculpher (ISPOR, ex-president)
  - to seek opportunities to collaborate and discuss statistical debates in HTA
- Commented on the 9 methods guides released by EUnetHTA on relative effectiveness and on the revision to the NICE methods guide
- Organised and presented at scientific meetings and conference sessions on HTA methods and trends
  - PSI 1-day HTA meeting (Nov ‘12)
  - DIA/FDA Biostatistics Workshop (Apr ‘13)
  - PSI 2013 Conference (May ‘13)
  - BBS HTA Seminar (Jun ‘13)
  - PSI training course ‘Network meta-analysis’ (Nov ‘13)
- Continue to research analytical methods relating to evidence synthesis, subgroup analyses in cost-effectiveness, and treatment crossover
  - 2 manuscripts drafted for Pharmaceutical Statistics

SIG: HTA

Plan for remainder of 2013:

- Update the HTA handbook, and reflect recent trends/changes in HTA agencies (e.g. UK, Germany and France)
  - Value-based pricing (UK)
  - Early assessment of clinical benefit (Germany)
- Keep abreast of IMI ‘GetReal’ (kick-off Oct ‘13)
- Network meta-analysis training (Nov ‘13)
  - PSI 2-day course
  - Options to record / make availabile to other country associations
- Submit 2 proposals for “statistics” focussed sessions at ISPOR 2013 EU conference
  - Research panel discussion: indirect comparisons, treatment crossover, choice of endpoints, subgroup analyses
  - Issue panel debate: integrating reimbursement needs in drug development programs
- Interest in ‘decision analysis’ and ‘value of information’ training

Key HTA News

- EUnetHTA release final relative effectiveness guidance
  - HTA core model for rapid relative effectiveness
  - 9 methodology guidelines



Endpoints used for REA of pharmaceuticals:

- Clinical endpoints
- Composite endpoints
- Surrogate endpoints
- Safety
- Health-related quality of life

Comparators and comparisons

- Criteria for the choice of the most appropriate comparator(s)
- Direct and indirect comparison

Levels of evidence

- Internal validity
- Applicability of evidence in the context of a relative effectiveness assessment

http://www.eunethta.eu/outputs/new-application-hta-core-model-hta-core-model-rapid-relative-effectiveness-assessment-pharma

Key HTA News (cont.)

- New permanent network of HTA agencies being

  Health Technology Assessment

  A permanent EU structure of cooperation to help decision-makers to make the right decisions on health investment and spending

- Collaboration between EMA and EUnetHTA
  - 6th meeting since 2010
  - Collaborate on scientific advice for drug development
  - Transparency of joint meetings (publish minutes of all meetings on both websites)
  - 3-year work program (Sept '13)

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001807.jsp&mid=WC0b01ac058004d5c1

PSI initiative towards SIGs

- PSI Board wants to run an advisory panel with senior figures in industry and share the outputs from that with the respective SIGs
  - particularly their take on “key issues coming up”
  - to see if this will trigger any ideas for the SIGs
- PSI will continue to support the efforts of SIGs to move the field forward and promote this

? New SIG ?
Meta-Analysis

Reasons for interest:

- FDA upcoming guideline on meta-analyses
  - Sep 2013: public meeting
  - Sep 2015: draft Guidance

- Increase of use and importance of meta-analyses:
  - in general (literature)
  - As part of pharmaco-vigilance (CIOMS)
  - as part of regulatory submissions
  - as part of HTAs (network meta-analyses)
  - in case of public disclosure of trial data (EMA)

PSI initiative towards SIGs

- PSI Board wants to run an advisory panel with senior figures in industry and share the outputs from that with the respective SIGs
  - particularly their take on “key issues coming up”
  - to see if this will trigger any ideas for the SIGs
- PSI will continue to support the efforts of SIGs to move the field forward and promote this

Back Up

What is a SIG ?

- comprise (usually) small groups of statisticians (and sometimes others) with a shared interest in a specific topic that is less furnished within the usual (statistical) societies, communities, etc.
- given the sufficient attention to clinical trial statistics, SIGs were set up in “new” areas like:
  - Benefit Risk
  - Health Technology Assessment (HTA)
  - Modeling & Simulation
- Used to be PSI SIGs and EFSPI SIGs but now all are open to both

SIG's purpose

Generally:

- To learn about, share and understand best practices in area of interest
- To discuss and make recommendations on key methodological issues
- To comment on or contribute to the development of guidelines
- To inform, share, and educate

SIG practically

- Largely self-sufficient
- No formal organization
- Most interactions by telecons, mails, but also (few) life meetings at site of participating company
- Often invited to co-organize scientific events
- produce papers (e.g., special issue of Pharmaceutical Statistics)

SIGs - Questions

- What do we expect from SIGs?
- What can SIGs expect from us?
- Should there be a less “voluntary” participation?
- Do we expect contributions from each company?
- Which SIGs should be “standard” to our community rather than “special interest”?
- What role can SIGs play to enhance our resiliance?